Class I regenerative treatments are procedures in the highest-risk category under Japan’s Act on the Safety of Regenerative Medicine. The classification requires specially certified committee review and additional national scrutiny; it does not mean a treatment is approved or effective.4980 Examples include procedures using embryonic or induced pluripotent stem cells, gene-modified cells, and certain donor-derived cells. In vivo gene therapy, which delivers genetic material directly into the body rather than modifying cells outside it, also entered this framework on 31 May 2025.Saisei_top_00005 On 30 June 2026, 8 of Japan’s 6,743 filed treatment plans were Class I, about 0.1%; these are plan counts, not patient numbers or success rates.001590173.pdf
What the Class I label means
This is a Japanese legal classification, not a worldwide treatment grade. The Act, No. 85 of 2013, groups covered procedures by their potential risk to human life and health.4980 Product approval follows a separate legal path. Do not treat a clinic’s filed provision plan as approval of the product or its advertised use.

What counts as Class I
- Procedures using embryonic stem cells or induced pluripotent stem cells, often shortened to ES and iPS cells.000855615.pdf
- Procedures using cells into which genes have been introduced or whose genes have been modified.000855615.pdf
- Procedures using certain donor-derived cells, including cultured allogeneic mesenchymal stromal cells. Allogeneic means the cells come from another person.000855615.pdf
- Covered in vivo gene therapies and related technologies brought into Class I by the changes effective 31 May 2025.Saisei_top_00005
These examples are not an exhaustive classification checklist. Many procedures using a patient’s own cultured cells are Class II rather than Class I; some platelet-rich plasma procedures are Class III. The exact cells, processing and use matter, so check the individual provision plan rather than classifying an offer from the words “stem cell therapy” alone.000855615.pdf
How Class I differs from Class II and III
The classes describe regulatory risk, not the likelihood that a treatment will help.
| Question | Class I | Class II | Class III |
|---|---|---|---|
| Rough meaning000855615.pdf | Higher regulatory concern; unfamiliar science or serious-risk potential | Medium regulatory concern; for example cultured autologous somatic-cell products | Lower regulatory concern; techniques outside Class I and II |
| Typical examples000855615.pdfSaisei_top_00005 | ES or iPS cell use, gene-modified cells, certain cultured donor-cell products, in vivo gene therapy | Many procedures using cultured cells from the patient, provided they do not meet Class I criteria | Procedures such as homologous platelet-rich plasma applications |
| Committee4980 | Must use a specially certified committee | Must use a specially certified committee | Certified committee |
| Where the plan goes4980 | Ministry of Health, Labour and Welfare, with national-level scrutiny | Regional bureau | Regional bureau |
| Waiting rule4980 | Normally a 90-day restricted period; MHLW may shorten or extend it | No equivalent Class I statutory 90-day restriction | No equivalent Class I statutory 90-day restriction |
What review a Class I plan must pass
Before treatment starts
A Class I plan starts with the hospital or clinic director writing a provision plan. It spells out the treatment, the facilities and staff, where the cells come from, how manufacturing and quality control work, what safety and ethics guards apply, and how consent and injury compensation are handled. A specially certified committee then reviews the plan.4980 Only 80 of Japan’s 167 certified committees held that special status on 30 June 2026.001590173.pdf
After submission to the Ministry of Health, Labour and Welfare, or MHLW, the normal restricted period is 90 days. The ministry may order changes if the plan falls short of provision standards. It may extend the period for reasonable grounds or shorten it when the plan conforms to the standards, notifying the institution accordingly. Provision cannot begin until the applicable period has expired.4980
After provision begins
The provider must keep records, report safety problems as required and submit periodic reports. MHLW can inspect institutions and issue improvement or emergency orders. Providing Class I regenerative medicine without submitting the required plan can attract up to one year of imprisonment or a fine of up to one million yen.4980
MHLW publishes institution names, treatment names, risk classes, committee names and consent-document forms. Research plans are disclosed through jRCT, Japan’s clinical-research submission and disclosure system.0000186471
A filing in the records means the paperwork exists. It never proves the treatment works.
What Class I does not prove
The June 2026 report separates treatment plans from research plans: there were 8 Class I treatment plans and 11 Class I research plans. Across all three classes, the totals were 6,743 treatment plans and 85 research plans. Neither total measures clinical effectiveness or explains why a particular procedure is uncommon.001590173.pdf
To assess benefit, ask about the exact treatment and its filing, the condition and disease stage, cell type, dose and administration route. What human studies tested that use? Ask for the study phase, participant numbers, comparison group, predefined outcomes, follow-up duration and adverse events. Animal findings or patient testimonials cannot establish benefit in people. A research registration confirms a record exists; it is not an efficacy result.
What risks and limits apply
Risks vary by the product and procedure. In its guidance on unapproved regenerative medicine products, the US FDA describes infections, unwanted immune or inflammatory responses, tumor formation and unintended tissue growth. These are general safety concerns, not estimates of how often harm occurs in Japanese Class I procedures.Important patient and consumer information about regenerative medicine therapies
Check the manufacturing status as well as the treatment plan. Japan’s framework distinguishes permission, notification and overseas accreditation for manufacturing facilities. A cell-processing facility’s regulatory status does not establish the clinical benefit of what it makes.4980 Before deciding, ask the treating physician to explain eligibility, alternatives, follow-up, foreseeable harms and the written arrangements for treatment-related injury.
How to check a Class I offer
- What is the exact treatment name as filed, and is it Class I, II, or III?
- Which medical institution filed the plan, and which specially certified committee reviewed it?
- What cells are used, from whom, how are they processed, and where does manufacturing happen?
- Is this treatment or research, and which consent and injury-compensation documents apply?
- What human evidence backs this exact use, and what are the known and uncertain risks?
- How is follow-up handled, and who takes responsibility if something goes wrong?
When an offer only says stem cell therapy
Ask for the filed treatment name, provision-plan number and medical institution’s legal name. Compare those details with the MHLW disclosure, then read the linked explanation and consent documents. Check whether the documented cells and intended use match what you were offered. If you cannot identify the plan or the details differ, ask the institution for a written explanation before deciding.0000186471
This document check can help identify the procedure and its regulatory route. It cannot establish whether the treatment will work for you or replace an individual medical assessment.
Preparing questions about a treatment offer?
Use the contact form for an inquiry. Ask the treating institution to confirm the plan, evidence and follow-up arrangements in writing.
Bottom line on Class I
Class I identifies Japan’s highest regulatory risk category, not its most effective treatments. The 8 Class I treatment plans recorded on 30 June 2026 show how small this category was in that snapshot, not how well those procedures worked.001590173.pdf Verify the individual plan, read the consent documents, and discuss the evidence and alternatives with the treating physician.




